IM naltrexone

Phase 3Small molecule

UUniversity of California, San Francisco

IM naltrexone is one of 7 small molecule programs targeting Overdose. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OverdoseRecruiting

OverdosePhase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Overdose

#DrugCompanyPhaseTrials

Narcan

SScienture

Approved

2 2

Suboxone

IIndivior Inc.

Approved

—3

IM naltrexone

UUniversity of California, San Francisco

Phase 3

1 4

Glucophage

EMD Serono

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

—6

Buprenorphine/naloxone

Astellas

Preclinical

—7

VORAXAZE

BBTG International Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2/3Recruiting

Overdose

NCT06633900

Clinical

Trials by Indication[1]

Overdose1 trial

Naltrexone for Overdose Prevention

Recruiting·UUniversity of California, San Francisco·Phase 2/3·NCT06633900·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IM naltrexone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IM naltrexone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IM naltrexone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of California, San Francisco

IM naltrexone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Overdose1 trial

References

Drug Info

Quick Facts

Related News